Padureanu Vlad, Forțofoiu Mircea-Cătălin, Donoiu Ionut, Tieranu Eugen-Nicolae, Dumitrascu Catalin, Padureanu Rodica, Mușetescu Anca Emanuela, Alexandru Cristina, Iorgus Carmen Catalina, Bobirca Florin, Dascalu Ana, Bobirca Anca
Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Department of Cardiology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Diagnostics (Basel). 2024 Dec 14;14(24):2819. doi: 10.3390/diagnostics14242819.
Coatomer subunit α (COPA) syndrome is a mendelian autosomal dominant immune dysregulation disease characterized by early onset lung disease in the form of diffuse alveolar hemorrhaging or interstitial lung disease, frequently associated with arthritis, glomerulonephritis, and high titer autoantibodies usually mimicking other autoimmune diseases. While immunosuppressive medication has been effective in controlling arthritis, data on long-term lung disease control remains scarce, which poses a real challenge as the progression of lung disease is the main cause of poor life expectancy in COPA patients. Nevertheless, JAK inhibitor therapy seems to be the most promising therapeutic choice now.
COPα综合征是一种孟德尔常染色体显性免疫失调疾病,其特征为以弥漫性肺泡出血或间质性肺病形式出现的早发性肺部疾病,常伴有关节炎、肾小球肾炎,以及通常类似于其他自身免疫性疾病的高滴度自身抗体。虽然免疫抑制药物在控制关节炎方面有效,但关于长期控制肺部疾病的数据仍然稀少,由于肺部疾病的进展是COPα综合征患者预期寿命不佳的主要原因,这构成了一个真正的挑战。尽管如此,JAK抑制剂疗法目前似乎是最有前景的治疗选择。